Fig. 2From: Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese populationKaplan-Meier analysis of progression-free survival in first line treatment populationBack to article page